Abbott in settlement with DexCom over continuous glucose monitors
by
Contributor since / Followers
Contributor since / Followers
13 hours ago
RichLegg/E+ via Getty Images
- Abbott (NYSE:ABT) has reached a settlement with DexCom (NASDAQ:DXCM) to resolve a patent dispute regarding continuous glucose monitors.
- The agreement dismisses all pending cases in courts and patent offices worldwide. In addition, neither company will bring patent, trade disputes, and design rights disputes with each other for the next 10 years.
- The settlement does not involve any payments between the two parties.
- Additional details are being kept confidential.